Archives
-
Cannabidiol for Orofacial Pain: Mechanisms and Evidence
2026-08-21
This 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce both inflammatory orofacial pain and associated anxiety-, depression-, and cognition-related deficits in mice. Its main contribution is a mechanistic framework linking peripheral CB2 signaling, central CB1-dependent endocannabinoid activity, and serotonin dynamics in the central amygdala.
-
Primidone: From TRPM3 Structure to Assay Design
2026-08-20
Primidone, also known as Mysoline, is more than an established anticonvulsant: it is a mechanistically informative probe for TRPM3, RIPK1, and related translational models. This guide converts structural and pharmacological evidence into practical assay-design decisions for ALS, neurodevelopmental, pain, and adenomyosis research.
-
Temafloxacin Against Gram-Negative Bacteria: Key Findings
2026-08-20
This reference study organizes comparative in vitro evidence for temafloxacin against respiratory pathogens, Enterobacteriaceae, sexually transmitted disease agents, and less common Gram-negative bacteria. Its principal contribution is a spectrum-level interpretation: temafloxacin showed strong activity against many organisms but was less active than ciprofloxacin against Pseudomonas aeruginosa, highlighting why organism-specific benchmarking remains essential.
-
MG-132 Workflows for Cell-Death Research
2026-08-19
MG-132, also known as Z-LLL-al, turns proteasome blockade into a practical tool for dissecting protein accumulation, apoptosis, cell cycle arrest, and oxidative stress. This workflow-oriented guide also shows how proteostasis perturbation can be paired with necroptosis models to test immunogenic anti-tumor effects without confusing cell death with inflammatory signaling.
-
Indometacin Enhances Endogenous Remyelination
2026-08-19
The reference study shows that indometacin can promote oligodendrocyte differentiation, myelination, and remyelination across cellular, ex vivo, and cuprizone-induced demyelination models. Its key contribution is linking this regenerative effect to GSK3β-dependent β-catenin phosphorylation, suggesting that an established NSAID may also influence repair biology beyond prostaglandin synthesis inhibition.
-
CNQX and Causal Mapping of Glutamate Circuits
2026-08-18
CNQX is more than an AMPA/kainate blocker: it is a causal probe for separating receptor-dependent circuit mechanisms. This article interprets CNQX results through the 2024 cNTS–PVN cardiovascular study and provides an assay-focused framework for neuroscience research.
-
Drosophila Keap1 Nuclear Condensates Under Oxidative Stress
2026-08-18
This study identifies a stress-responsive nuclear condensate function for Drosophila Keap1, linking its domain architecture to changes in protein mobility and intracellular organization. Domain deletion, FRAP, fluorescence imaging, and in vitro reconstitution show that the C-terminal region promotes condensate formation, whereas the Kelch domain suppresses it.
-
NU7441 and DNA-PK: From Mechanism to Translation
2026-08-17
NU7441, also known as KU-57788, offers a selective way to interrogate DNA-PK-dependent repair, cell-cycle control, and cancer sensitization. This thought-leadership article connects mechanistic DNA repair research with translational assay design, using HIV latency findings as a carefully bounded framework for identifying DDR vulnerabilities.
-
Tetraethylammonium Chloride for K+ Studies
2026-08-17
Tetraethylammonium chloride (TEAC) provides a practical, reversible way to challenge potassium-channel-dependent signaling in electrophysiology, secretion assays, and vascular preparations. This guide translates its dual-site pore-blocking mechanism into workable protocols, controls, and troubleshooting strategies while clarifying why TEAC is a blocker rather than a subtype-selective probe.
-
AMG 9810 TRPV1 Antagonist Workflows
2026-08-16
AMG 9810 provides reversible, competitive control of TRPV1 for calcium imaging, CGRP release, and sensory neuron signaling studies. This workflow pairs robust antagonist testing with stress-aware controls inspired by recent AMPK–SQSTM1 research, without overstating an unproven TRPV1–metabolic pathway.
-
p-Tau Ser356 and NUAK Inhibition in Alzheimer’s Disease
2026-08-15
Taylor et al. characterize tau phosphorylation at Ser356 as a pathology-associated feature of Alzheimer’s disease and show that NUAK inhibition produces distinct responses in mouse and human brain slice cultures. The study supports site-specific tau analysis while highlighting important limits in translating pharmacological effects between experimental systems.
-
Acetylcholine Chloride in Gut-Brain Assays
2026-08-14
Learn how Acetylcholine Chloride can serve as a defined cholinergic stimulus for separating receptor activity, vagal signaling, and microbiota-associated effects. This workflow-focused guide covers fresh-solution preparation, dose-response design, assay controls, and troubleshooting for gut-brain and neuroscience experiments.
-
Calpeptin Workflows for Pulmonary Fibrosis Research
2026-08-14
Calpeptin provides a practical way to perturb calcium-dependent cysteine protease activity while tracking fibrosis, inflammation, and cell-death outcomes in parallel. This guide translates product specifications and cell-death biology into reproducible workflows, assay controls, and troubleshooting strategies for pulmonary fibrosis research.
-
Cepharanthine in Organoid and In Vivo Models
2026-08-13
Cepharanthine connects rapid stromal-cell screening with patient-derived endometrial organoids and an in vivo lesion model. This workflow helps distinguish broad cytotoxicity from cell-cycle arrest, DNA-damage signaling, and mitochondrial apoptosis while providing practical formulation and troubleshooting guidance.
-
Carbon-Ion Radiotherapy, DHODH, and Ferroptosis
2026-08-13
Wang and Cai show that carbon-ion radiotherapy suppresses gastric cancer through a linked mechanism involving DHODH downregulation, ferroptosis, and M1-like macrophage polarization. The study provides a mechanistic framework for examining DHODH as a modifier of carbon-ion treatment response, while its cell-line and xenograft design indicates that clinical translation will require further validation.